May 16, 2025

FDA Approves PD-1–Targeted Monoclonal Antibody for SCAC

The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.

Conexiant

May 16, 2025

Upadacitinib Maintains UC Remission Through 96 Weeks

A 3-year study found that most patients with moderate to severe ulcerative colitis who responded to initial upadacitinib treatment stayed in remission through 96 weeks, with manageable side effects and consistent results across dosage groups.

Conexiant

May 13, 2025

Appendectomy Cuts UC Relapse Rates, Study

Appendicectomy may significantly reduce relapse rates within 1.

Conexiant

May 07, 2025

Pancreatitis Prevention: Just a Myth?

A major study finds no benefit from a common surgery long used to prevent pancreatitis.

Reuters

May 05, 2025

Ustekinumab Biosimilar Receives Interchangeability Approval

Selarsdi (ustekinumab-aekn) was approved by the FDA as an interchangeable biosimilar to Stelara (ustekinumab) for all approved indications, including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Conexiant

April 28, 2025

Oral Contraceptives Linked to Gut Gas Shifts

Researchers found oral contraceptives alter gut bacteria and breath gas levels differently depending on menstrual cycle timing.

Conexiant

April 25, 2025

Cinnamon Oil May Trigger Drug Interactions

Cinnamaldehyde may modestly activate drug-metabolizing receptors, raising potential herb–drug interaction concerns.

Conexiant

April 25, 2025

Gut-Friendly Diet Linked to Lower Diabetes Risk

A study of over ten thousand US adults found that a gut-friendly diet was linked to lower risk of type 2 diabetes and insulin resistance.

Conexiant

April 24, 2025

Vitamin D Multifaceted CRC Immunomodulator Revealed

"Vitamin D enhances immune organ functions such as the spleen and lymph nodes, and boosts T-cell activity, which is essential in defending the body against tumors."

Conexiant